Belinda M. Juran’s practice focuses on advising clients on technology-centered transactions. She helps biotechnology, pharmaceutical, medical device, high technology and service companies achieve their strategic goals by advising them on all phases of their product development and commercialization relationships.
Ms. Juran negotiates and advises clients on collaboration, development, distribution, license and service agreements with customers, suppliers, licensors, licensees and other third parties, and on the acquisition and sale of intellectual property and joint venture arrangements.
She works with clients on matters ranging from bet-the-company billion-dollar global strategic collaborations to day-to-day issues. Ms. Juran also has provided general corporate advice to public and private companies and has represented companies in venture capital financings, initial public offerings and mergers and acquisitions.
She also works closely with WilmerHale’s IP litigation team, negotiating settlement and license agreements to settle ANDA and other litigation matters. Ms. Juran provides her clients with practical insights by combining her experience and education in technology, business and law.
Prior to practicing law, Ms. Juran worked in the high technology industry for several years, where she developed sophisticated computer-aided engineering software, then managed engineering departments. She has also been a consultant to several high technology companies.
Ms. Juran sits on the board of directors of UTEC, the United Teen Equality Center of Lowell, Massachusetts. Through job training, education and social support, UTEC enables Lowell’s most disconnected young people to trade violence and poverty for social and economic success.
Experience :
- Has represented Infinity Pharmaceuticals in its significant collaborations, including Infinity’s broad drug discovery collaboration with Purdue and the restructuring of that relationship, and Infinity’s collaboration with Intellikine on PI3K and the restructuring of that relationship
- Has represented Synta Pharmaceuticals in several development and commercialization collaboration, including with Hoffman-La Roche for drugs to treat inflammatory diseases
- Represented Enobia Pharma in the negotiation of the earn-out provisions in its acquisition by Alexion Pharmaceuticals, which may entitle Enobia’s stockholders to up to $470 million in milestone payments in addition to the $610 million paid up-front in cash
- Has represented Aciex Therapeutics in several transactions, including an ophthalmic collaboration with Portola Pharmaceuticals
- Represented Montreal-based Bellus Health in several transactions, including the acquisition of rights to eprodisate by Celtic Therapeutics.
- Represented Rhythmia Medical in several transactions, including the negotiation of earn-outs in its acquisition by Boston Scientific
- Represented Durata Therapeutics in the acquisition of RaQualia’s Japanese rights to dalbavancin, a MRSA compound.
EDUCATION :
- JD, Harvard Law School, 1998
- MBA, Boston University, 1995
- BS, Mathematics, University of Scranton, 1981
ADMISSIONS : Massachusetts
Cost
Rate : $$$
